Acurx Pharmaceuticals, Inc.
NASDAQ:ACXP
Overview | Financials
Company Name | Acurx Pharmaceuticals, Inc. |
Symbol | ACXP |
Currency | USD |
Price | 0.699 |
Market Cap | 13,626,096 |
Dividend Yield | 0% |
52-week-range | 0.68 - 5 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. David P. Luci CPA, CPA, Esq., J.D. |
Website | https://www.acurxpharma.com |
An error occurred while fetching data.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD